NeoPharm, Inc. (Lake Forest, IL; 847-295-8678) announced that new preliminary human clinical data on the company's entire Phase I portfolio of cancer treatment agents was released this week at the 38th American Society of Clinical Oncology (ASCO) Annual Meeting held in Orlando, Florida from May 18-21, 2002. ASCO accepted all nine (9) scientific abstracts submitted for NeoPharm's products in Phase I clinical development using the company's proprietary NeoLipid Electrostatic Liposome Encapsulation and Tumor-Targeting platforms. Preliminary data from four NeoPharm compounds in Phase I clinical trials, as presented in two scientific posters and published in the 2002 ASCO Program Proceedings (Volume 21), indicated that these ongoing clinical studies provided early evidence of patient safety, tolerability and successful dose escalation. Although not designed as efficacy studies, early data from these Phase I trials in certain populations of individuals suggested a preliminary treatment effect.
"NeoPharm is dedicated to developing effective, novel and well-tolerated therapies to benefit patients with cancer and to serve unmet medical needs. As evidenced by ASCO's acceptance of our scientific research in collaboration with our strategic partners and study investigators, we're moving ahead with the transformation NeoPharm into an integrated biotechnology company that will have the ability to bring compounds from conception to commercialization," said James Hussey, President and Chief Executive Officer of NeoPharm. "ASCO is yet another example of …
No comments:
Post a Comment